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Abstract
TNF-α is a highly pleiotropic cytokine and plays an important role in regulating HIV-1
replication. It may compromise the integrity of the blood-brain-barrier and, thus, may contribute to
the neurotoxicity of HIV-1-infection. Both intravenous drug abuse (IDU) and HIV infection can
increase TNF-α activity, but little information is available on the effects of a combination of these
factors on TNF-α. We investigated plasma TNF-α levels and mRNA in the peripheral monocytes
of 166 men and women in three groups: HIV-1-positive IDUs, HIV-1-negative IDUs, and HIV-
negative non-IDU control participants. HIV-1-positive IDUs had higher TNF-α levels than
HIV-1-negative IDUs who, in turn, had higher levels than controls. TNF-α mRNA expression in
peripheral monocytes was significantly increased in both HIV-1-positive and negative IDUs
compared to controls. These findings show that the effects of HIV infection and intravenous drug
use may be additive in increasing TNF-α levels. Given the multiple effects of TNF-α in HIV
infection, additional investigation of its role is needed.
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Introduction
Injecting drug use (IDU) is a major risk factor for contracting human immunodeficiency
virus type 1 (HIV-1), infection and accounts for almost one third of all cases of HIV-
infection (Balode et al. 2004; Donahoe and Vlahov 1998). Research suggests that IDU and
HIV-1 infection intertwine to bring about increased viral replication, immune suppression,
and neurotoxicity (Abdala et al. 2003; Fernandez et al. 2001; Nath et al. 2002). Although
neurodegeneration is one of the major complications in HIV-1 infection (Wang et al. 2004;
Nath et al. 2002), its mechanisms are not fully understood. One proposed pathway for the
neurodegenerative processes seen in HIV-1 infection implicates proinflammatory cytokines
that are elevated among HIV-1-infected individuals.
Tumor necrosis factor-alpha (TNF-α) is one of the most important proinflammatory
cytokines. It is primarily produced in the peripheral cells including activated monocytes or
macrophages (Beutler and Cerami 1989). TNF-α levels are elevated in persons with HIV-1
infection (Molina et al. 1989; Roux-Lombard et al. 1989; Fauci 1996), and this elevation
may have important implications for the course of HIV infection (Lawn et al. 2001). Earlier
reports demonstrated that TNF-α stimulated HIV replication in a variety of cells and that its
mRNA levels were higher in HIV-seropositive compared to uninfected brain tissue (Tyor et
al. 1992; Wesselingh et al. 1993; Brown et al. 1994; Biswas et al. 1994; Weissman et al.
1994). Moreover, increased secretion of TNF-α and other proinflammatory cytokines has
been reported in monocytes isolated from peripheral blood (Merrill et al. 1989; Nakajima et
al. 1989; Wahl et al. 1989) and cultured cells from HIV-positive individuals (Breen et al.
1990; Fauci 1996; Molina et al. 1989; Roux-Lombard et al. 1989). TNF-α alone or in
synergy with other cytokines may upregulate HIV replication and production in host cells
(Fauci 1996; Poli 1999).
TNF-α has also been related to cognitive function in several populations, supporting its
possible role in neurodegeneration. The possible role of TNF-α in HIV-related cognitive
decline was recognized some time ago (Matsuyama et al. 1991). TNF-α levels are related to
cognitive decline in HIV-infected individuals (Rostasy et al. 2005; Sevigny et al. 2004,
2007). A possible link between TNF-α and cognition may be through proinflammatory
cytokines’ ability relation to depression (Pucak & Kaplin 2005) and the inhibition of
hippocampal neurogenesis in depression (Henn & Vollmayr 2004; Sapolsky 2004). Since
substance use has clear and complex effects on cognitive function (Ersche et al. 2006;
Verdejo-García & Pérez-García 2007), the effects of drugs on cognition may also be
mediated by proinflammatory cytokines such as TNF-α, further demonstrating the
importance of TNF-α in understanding the relations among HIV infection, drug use, and
inflammatory cytokines.
Research has also shown that TNF-α levels are increased by exposure to commonly used
drugs of abuse including opioids (Roy et al. 1998) and methamphetamine (Nakajima et al.
2004). Cocaine use may decrease production of TNF-α (Irwin et al. 2007) although HIV-1-
infected cocaine users have been found to have elevated levels of TNF-α (Letendre et al.
1999). IDU is a major risk factor for HIV-1 infection, and it is, thus, possible that IDU may
affect the course of HIV infection through its effects on cytokine production. Little
information is available, however, on TNF-α levels in HIV-positive injecting drug users.
This study investigated plasma TNF-α levels and its peripheral monocyte mRNA expression
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in three groups: HIV-positive IDUs, HIV-negative IDUs, and HIV-negative nondrug using
control participants. We hypothesized that levels of plasma TNF-α and monocyte TNF-α
mRNA expression would be increased by both intravenous drug use and HIV infection.
Methods
Participants
Men and women within the age range of 18 to 50 years were enrolled for this study. All
participants gave informed consent prior to initiation of the study, and all participants were
paid for their participation. Potential participants were excluded from participation if they
reported a history of head injury with loss of consciousness, learning disability, or a history
of major psychiatric illness such as schizophrenia or bipolar disorder, hypertension, or
diabetes mellitus. The study was conducted under a protocol approved by the University of
Miami Human Subjects Research Office.
Drug use inclusion and exclusion criteria
Men and women in IDU groups were required to have used injected drugs, i.e., heroin and/
or cocaine, at least six times in a 1-year period. All participants were interviewed using the
Structured Clinical Interview for DSM-IV Axis I Diagnosis through which a diagnosis of
dependence or abuse on a particular substance was made. To qualify for the study as a
control participant, the individual could have no current or recent past substance
dependence; however, individuals with past substance abuse diagnoses were not excluded if
the substance abuse had been in remission for at least 2 years. Individuals with a current
substance abuse or dependence diagnosis who did not meet the criteria for injection drug use
were excluded from participation. All participants also completed a comprehensive lifetime
drug use interview that detailed information about drug use patterns with all forms of
cocaine, opiates including heroin, marijuana, anxiolytics, and amphetamines. All IDU
participants were required to have abstained from drugs and/or alcohol for at least 12 h prior
to the study. This was verified by self-report and urine toxicology screens. If a participant
was found to be acutely intoxicated, he or she was rescheduled for evaluation at a later date.
HIV-1 infection inclusion and exclusion criteria
HIV-1-positive participants were required to bring evidence of their serostatus to the study.
Additionally, their peripheral plasma viral load was determined using polymerase chain
reaction (PCR) amplicor method (Roche Diagnostics; at the Clinical Immunology
Laboratory in the Department of Medicine, the University of Miami School of Medicine).
HIV-1-positive participants were free of any AIDS-defining infections at the time of the
study. Verification of HIV-1 seronegative status was not done as part of this study.
Cold pressor stress
The cold pressor challenge was performed between 8:00 A.M. and 11:00 A.M. On arrival, an
indwelling venous catheter for drawing blood was placed in the antecubital vein of each
participant. After 20 min of rest in a reclined position, a 9-ml sample of blood was drawn in
a tube containing EDTA to determine participants’ baseline level of TNF-α. The cold
pressor challenge was then administered. Participants placed their entire hand in an ice–
water mixture (three parts ice and one part water) for 2 min. Following completion of the
cold pressor challenge, three additional blood samples were collected at 15, 30, and 50 min
after baseline.
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Laboratory procedures
Plasma isolation: Blood was collected in tubes with EDTA added as an anticoagulant.
Samples were centrifuged at 1,000×g within 30 min and stored at −20°C until analyzed.
Plasma TNF-α protein analysis: Levels of plasma TNF-α (pg/ml) were quantified using a
commercially available ELISA kit (R&D Systems, Minneapolis, MN, USA). Briefly, 50μl
of assay diluent were added to wells containing 200μl of standard or sample. The mixture
was incubated at room temperature for 2 h. Wells were washed three times in an ELISA
washer; 200μl of conjugated antibody were added to each well and samples were then
incubated for 2 h at room temperature. Washing was then repeated, and 200μl of substrate
solution was added to each well and incubated further for 20 min at room temperature. Fifty
microliters of stop solution were added to each well and read at 450 nm within 30 min.
Correction for OD at 540 nm was applied. The minimum detectable concentration of TNF-α
by this method is 4.4 pg/ml.
Monocyte isolation: Monocytes were separated from 10 ml of whole blood, using the
Mono–Poly resolving medium, Ficoll-Hypaque gradient (ICN Biochemicals) and washed
twice with sterile phosphate-buffered saline. Monocyte pellets were stored in RNA-later
(Ambion) solution at −80°C.
RNA isolation and TNF-α real-time RT-PCR: Total RNA was extracted from monocytes
using a commercially available kit, and TNF-α mRNA expression was determined using
Real-time RT-PCR. RNA was extracted from the cells using the RNeasy kit (Qiagen).
Transcription and amplification was carried out using Real-time PCR (Model ABI Prism
7000 system, Applied Biosystems). One microgram of total RNA was reverse transcribed
using a high capacity kit (Applied Biosystems) in a total volume of 20μl. Reverse
transcription was carried out at 25°C for 10 min and at 37°C for 120 min. Transcribed
cDNA was amplified using commercially available predeveloped primer pairs and Taqman
probes (Applied Biosystems). Amplification was carried out at 50 for 2 min then at 95°C for
10 min. Forty-five amplification cycles were then completed at 95°C for 15 s/cycle.
Concentration of each sample was calculated from the threshold cycle (Ct) and normalized
according to the 18s rRNA (as a housekeeping gene) levels. A standard curve for the gene
studied was generated by preparing serial dilution of the cDNA sample obtained from the
monocytes isolated from the blood.
Data analyses: Data were examined for outliers and influential data points via analyses of
means and standard deviations with a cutoff value of ±4 SD from the mean. In those cases
where removal of the outlying data point resulted in a meaningful change in the results, the
outlying data point was excluded from the analyses. Potential covariates evaluated in this
study were: age, ethnicity, body mass index, education, gender, and drug use characteristics
including duration of use of cocaine and heroin. In order to evaluate whether cocaine and
heroin had divergent effects on TNF-α, an indicator variable for persons who used one but
not the other substance was created and included in models. The effects of viral load and any
antiretroviral treatment were also included as potentially important covariates.
To test the hypothesis that the three study groups would differ in plasma TNF-α levels, a
mixed effects repeated measures model was created using SAS PROC MIXED (SAS, Inc.,
Cary, NC, USA). Random effects included in the model allowed an evaluation of individual
differences in baseline TNF-α (intercept) as well as of differences in change over time
(slope). Fixed effects included potential confounding variables as well as group
membership. To assess group differences in mRNA levels, only a random intercept model
was evaluated as mRNA was measured on only one occasion. This approach has the
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considerable advantages of allowing for individual variability in baseline variables and
change over time and a more precise determination of the relation of group-level variables to
outcomes of interest (Finucane et al. 2007).
Results
Participants in this study included 166 men and women in three study groups: HIV + IDUs
(N = 56), HIV – IDUs (N = 59) and HIV-nondrug using control participants (N = 51). Of
these 166 men and women, TNF-α gene expression assay for mRNA was conducted in 69
participants (HIV-positive IDUs (N = 30), HIV-negative IDUs (N = 19), and HIV-negative
nondrug using control participants (N = 20)).
Demographic characteristics and levels of TNF-α and TNF-α mRNA of the participants are
presented in Table 1.
The groups differed significantly in age, years of education, and body mass index. The
groups differed in their gender and ethnic compositions as well. Simple one-way analyses of
variance showed group differences at each time point for TNF-α and overall group
differences for mRNA, but it should be noted that these analyses are not corrected for
participants’ drug use characteristics and demographic differences (for which, see Tables 3,
4, 5, and 6). Figures 1 and 2 present scatter plots of TNF-α levels for each group at each
sampling time and for baseline TNF-α mRNA values, respectively.
Comparisons of self-reported drug use histories and length of abstinence are presented in
Table 2. HIV + participants reported significantly longer abstinence from anxiolytics and
heroin but significantly shorter abstinence from cocaine compared to HIV− participants.
The hypothesis of group differences in TNF-α levels was evaluated using a mixed effects
repeated measures model that allowed individuals’ baseline level of TNF-α and the time
course of their response to cold pressor stress to vary. Results are presented in Tables 3 and
4. Controls had the lowest levels of TNF-α, while HIV− and HIV+ IDUs had progressively
higher levels. All between-group comparisons were statistically significant. Men had model-
corrected values that were larger than those for women. TNF-α levels did not change over
time after participants experienced cold pressor stress (i.e., we found a nonsignificant effect
for time; see Tables 3 and 4).
Analyses of group differences in mRNA levels were completed using a similar model but
with only a random intercept as mRNA levels were measured on only one occasion (at
baseline). Both IDU groups had higher levels of mRNA compared to controls. Length of
abstinence from cocaine and viral load were positively related to mRNA levels (Tables 5
and 6).
Discussion
In this study, we assessed the TNF-α levels in intravenous drug users who were either
infected or not infected with HIV-1 and compared their levels to those of uninfected and
nondrug using controls. All experienced cold pressor stress as part of their participation in a
larger study of neurohormonal changes in HIV− and HIV+ individuals. We found that
participants’ levels of TNF-α reflected the effects of both intravenous drug use and HIV
infection, with those with both characteristics having the highest levels of TNF-α. TNF-α
mRNA was similarly elevated in both IDU groups, although in these comparisons the
difference between levels in HIV− and HIV+ individuals was not statistically significant.
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Earlier studies from our group showed that elevated TNF-α levels might be related to
neurodegeneration (Kumar et al. 2002, 2003). Other investigators have shown that HIV-1
infection is characterized by a significant increase in the levels of proinflammatory
cytokines, predominantly secreted by activated monocytes that are storehouses of the virus
(Breen 2002). As the equilibrium between Th1 and Th2 cytokines is disturbed in HIV-1
infection, this imbalance may lead to clinical disease progression related to increased Th1
activity. TNF-α can be considered a Th1 cytokine, has been associated with increased
HIV-1 replication, and is highly neurotoxic (Nakajima et al. 2004). Variability in virus
strains’ ability to elicit TNF-α increases may be related to the different disease courses
causes by these strains (Khanna et al. 2000).
The role of TNF-α in HIV-related cognitive decline was recognized long ago (Matsuyama et
al. 1991). High levels of TNF-α are associated with compromise of the blood-brain barrier
(Brabers & Nottet 2006;Vandamme et al. 2004; Pu et al. 2003). With disruption in the
blood-brain barrier, HIV-containing monocytes can enter the brain and may infect microglia
(Pu et al. 2003, Annunziata 2003). Earlier reports demonstrate that both HIV-infected
monocytes and microglia secrete large amounts of TNF-α (Sippy et al. 1995). TNF-α is
associated with cognitive decline and mortality in HIV-infected individuals (Rostasy et al.
2005; Sevigny et al. 2004, 2007). Several lines of evidence, thus, show that level of TNF-α
is associated with severity and progression of HIV-related diseases, including cognitive
impairment (Brabers & Nottet 2006).
The molecular mechanism for upregulation of HIV expression by proinflammatory
cytokines is best characterized for TNF-α. TNF-α activates NF-κB, a transcription factor
that is sequestered in its active form in the cytoplasm of cells (Fauci 1996; Poli 1999). Once
activated, NF-κB translocates to the nucleus, binds near the transcription start site of HIV
(located near the long terminal repeat sequences of the viral genome), and initiates and/or
enhances HIV expression and viral production. HIV infection itself increases levels of TNF-
α which can in turn affect viral replication (Leghmari et al. 2008).
Although data on TNF-α levels are available for HIV+ individuals, no readily identifiable
study has compared TNF-α levels in HIV+ and HIV− IDUs. The study presented here
demonstrates differences in TNF-α levels and TNF-α mRNA across these groups and in
comparison to controls. TNF-α levels were increased in HIV− IDUs and were still higher in
HIV+ IDUs. This suggests that the effects of HIV infection on TNF-α production are
increased relative to drug use alone. This finding is, thus, significant for understanding the
role of proinflammatory cytokines in the progression of neurodegeneration and
neurocognitive deficits in individuals affected by both conditions.
Other studies have shown increases in TNF-α levels (Tyor et al. 1992), associated mRNA
(Wesselingh et al. 1993) and receptors (Sippy et al. 1995) in the brains of HIV-1-infected
individuals. A relation between TNF-α and HIV-associated cognitive deficits has also been
reported (Sippy et al. 1995) and we have previously shown that cognitive functioning in
HIV + IDUs may be affected by the neurohormonal response to stress (Ownby et al. 2006).
The study reported here evaluated the relation between the TNF-α mRNA and intravenous
drug use and HIV infection. We found that mRNA levels were elevated in both groups of
IDUs. Although the model-corrected level of mRNA was higher in IDUs with HIV infection
than in those without, the difference was not statistically significant. It is, thus not clear
whether the incremental effect of HIV infection on TNF-α levels is related to increased
TNF-α production or to some other factor.
Several limitations of this study should be noted. This study did not include a group of
participants who were HIV+ but not intravenous drug users. While this inclusion would
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have been desirable, given the context in which the study was completed inclusion of a
fourth group of participants was not possible. Another issue that may affect study results is
the divergent characteristics of the groups of participants, who varied with respect to age,
education, body mass index, and drug use severity and abstinence. Although these issues are
statistically controlled in data analyses, between-group differences may have affected results
in ways that cannot be predicted. It should also be noted cold pressor stress did not
significantly affect TNF-α levels over the sampling intervals used in this study. This is
likely due to the time frame in which samples were collected, which was based on interest in
plasma catecholamines and cortisol in the parent study. In fact, data on the levels of
catecholamines and cortisol showed a clear and robust effect of cold pressor stress that we
have reported elsewhere (Ownby et al. 2006). The apparent lack of effect on TNF-α is, thus,
likely the result of the time course of sampling.
These findings, thus, show that levels of TNF-α are increased both by intravenous drug use
and HIV-1 infection. Since intravenous drug use is an important risk behavior related to HIV
infection, it is important to note that drug use itself may affect immune system factors that
may be neurotoxic and have been related to cognitive function. The additional finding that
HIV-1 infection may be an additive factor in increasing TNF-α and, thus, in increasing risk
for cognitive impairment underscores the importance of addressing both issues in future
research. Additional research on the effects of intravenous drug use and HIV infection on
immune factors and cognitive functioning is, thus, indicated.
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Fig. 1.
TNF-α levels for each group at each sampling point. Squares=controls; crosses=HIV
negative IDUs; circles=HIV positive IDUs
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Fig. 2.
TNF-α mRNA for each group
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Table 1
Characteristics of study participants
Controls HIV− IDUs HIV+ IDUs Statistic df p Value
Age in Yearsa M (SD) 32.2 (9.1) 38.7 (6.4) 39.1 (5.5) F = 15.58 2, 162 <0.001
Years of Educationb M (SD) 13.7 (2.1) 11.7 (2.0) 12.1 (2.0) F = 13.92 2, 161 <0.001
BMIc M (SD) 27.7 (5.9) 24.8 (4.6) 26.1 (5.3) F = 4.37 2, 158 0.016
Log Baseline TNF-αd M (SD) 1.49 (.30) 1.99 (.33) 2.45 (.26) F = 140.48 2,163 <0.001
Log TNF-α at 15 minutes M (SD) 1.41 (.49) 2.00 (.31) 2.44 (.25) F = 109.96 2,164 <0.001
Log TNF-α at 30 minutes M (SD) 1.48 (.26) 1.93 (.36) 2.43 (.27) F = 128.04 2,162 <0.001
Log TNF-α at 50 minutes M (SD) 1.45 (.49) 2.00 (.30) 2.39 (.28) F = 88.47 2,163 <0.001
Log TNF-α mRNAe M (SD) 22.81 (1.71) 24.46 (.99) 24.82 (.98) F = 16.50 2, 66 <0.001
Genderf Male 23 44 36 χ2=10.27 2 0.006
Female 28 15 20
Ethnicity White 10 20 4 χ2=23.31 4 <0.000
Black 24 21 43
Hispanic 17 18 9
aComparisons for continuous variables were completed with one-way analysis of variance with Scheffé post hoc comparisons. Controls were
significantly younger than either IDU group (p<0.001 for both comparisons)
bControls reported significantly more years of education than did either of the other two groups (p<0.001 for both comparisons)
c
BMI was significantly higher in controls compared to HIV− IDUs (p=0.016)
dAll Scheffé between-group comparisons for TNF-α were statistically significant (all p<0.001)
eScheffé between-group comparisons for TNF-α mRNA showed a statistically significant difference between controls and HIV− IDUs (p<0.001)
but not for the difference between HIV− IDUs and HIV+ IDUs
fComparisons of categorical variables were completed using Pearson chi-square statistics
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Table 2
Drug use characteristics of HIV− and HIV+ IDUs
HIV− IDUs HIV+ IDUs t df a p Value
Mean SD Mean SD
Length of time used (weeks)
 Anxiolytics 99.24 98.16 126.60 230.72 −.68 46.69 .50
 Marijuana 314.58 310.95 433.03 453.29 −1.51 82.38 .13
 Heroin 289.95 322.08 278.20 397.07 0.17 103 .87
 Cocaine 225.61 325.36 287.77 305.15 −.94 89 .35
 Crack cocaine 241.80 334.99 336.40 349.43 −1.30 86 .20
Length of abstinence (weeks)
 Anxiolytics 721.00 953.67 1431.83 906.96 −3.45 83 <0.001
 Marijuana 354.60 545.99 363.84 657.02 −0.07 91 .94
 Heroin 193.01 572.61 836.07 1072.73 −3.75 71.37 <0.001
 Cocaine 645.40 975.80 224.54 505.31 2.67 72.66 .01
a
Degrees of freedom vary across tests due to some questions not being relevant to some participants (i.e., never having used the substance and,
thus, not reporting either use or abstinence). For comparisons in which group variances differed, a correction to degrees of freedom was applied
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Table 3
Mixed effect model for TNF-α levels
Fixed effects Numerator df Denominator df F p value
Time 3 248 1.35 0.26
BMI 1 134 0.00 0.98
Age 1 134 0.53 0.47
Ethnicity 2 134 0.88 0.42
Gender 1 134 3.27 0.07
Education 1 134 0.08 0.77
Cocaine Use Intensity (grams/wk) 1 134 0.43 0.51
Length of Cocaine Abstinence 1 134 2.45 0.12
Heroin Use Intensity (injections/wk) 1 134 1.49 0.22
Length of Heroin Abstinence 1 134 0.17 0.69
Viral Load 1 134 0.01 0.92
ARV Treatment 1 134 0.01 0.92
Cocaine User Only 1 134 0.63 0.43
Heroin User Only 1 134 0.52 0.47
HIV/IDU Status 1 142 99.30 <0.001
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Table 4
Model-corrected mean TNF-α values
Group Estimate Standard error
Controls 1.60a 0.09
HIV− IDUs 1.92a 0.07
HIV+ IDUs 2.50a 0.08
Men 2.06b 0.05
Women 1.95b 0.06
Cocaine and heroin users 1.97c 0.05
Cocaine and not heroin user (n=94) 2.03c 0.07
Heroin and not cocaine user (n=30) 2.04c 0.09
aAll comparisons between model-adjusted mean values for participant groups were significantly different (p<0.001)
b
Difference between men and women was significantly different (p=0.04)
c
Differences between individuals who reported using cocaine but not heroin and those reporting heroin use but not cocaine and all other individuals
were not significant (cocaine only vs. others, p=0.43; heroin only vs. others, p=0.47). The majority of participants reported polysubstance use
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Table 5
Mixed effect model for TNF-α mRNA
Fixed effects Numerator df Denominator df F p Value
BMI 1 46 0.04 0.84
Age 1 46 2.98 0.09
Ethnicity 2 46 3.17 0.05
Gender 1 46 0.36 0.55
Education 1 46 0.47 0.50
Cocaine Use Intensity (grams/wk) 1 46 0.91 0.34
Length of Cocaine Abstinence 1 46 3.94 0.05
Heroin Use Intensity (injections/wk) 1 46 1.38 0.25
Length of Heroin Abstinence 1 46 0.62 0.44
Viral Load 1 46 6.47 0.01
ARV Treatment 1 46 2.62 0.11
Cocaine User Only 1 46 0.75 0.39
Heroin User Only 1 46 0.08 0.79
HIV/IDU Status 2 59 5.30 0.009
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Table 6
Model-corrected mean log TNF-α mRNA values
Group Estimate Standard error
Participant groupsa
 Controls 22.32 0.65
 HIV− IDUs 24.74 0.42
 HIV+ IDUs 24.75 0.49
Ethnic groupsb
 Whites 24.47 0.45
 Blacks 24.21 0.40
 Hispanics 23.13 0.51
aComparisons between controls and HIV− IDUs was significant (t (46)=−3.10, p=0.003); between controls and HIV+ IDUs was significant (t
(46)=−3.08, p=0.004); between HIV− and HIV+ IDUs was not significant (t (46)=−0.01, p=0.99)
bComparisons between values for ethnic groups; between whites and blacks not significant (t (46)=.52, p=0.61); whites and Hispanics (t (46)=2.30,
p=0.03); blacks and Hispanics (t (46)=2.21, p=0.03)
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